NLSP רווח נקי למניה ב-12 החודשים האחרונים nlspharma.com

NLS Pharmaceutics AG is developing promising treatments for ADHD and narcolepsy, leveraging a strictly controlled drug distribution system. Analyzing the 12-month EPS trend chart on GURU.Markets, it is evident that -1.74 determines the latest valuation metric. The company is currently in the clinical testing stage without active cash flow, operating on its existing capital.

NLS Pharmaceutics AG (NLSP) is currently focusing on expanding its neuro-drug portfolio through strategic mergers and acquisitions. By analyzing the TTM net income per share on the GURU.Markets platform, an investor can see the final financial result distributed across the entire volume of the issue. This metric measures the real return on each share of capital over a rolling year. This chart reflects the business's ability to generate profit in an environment of expensive borrowed capital. However, to assess resilience to M&A transactions, this indicator should be compared with the level of debt load.